IDEAYA Biosciences Inc（简称IDEAYA）于2026年4月8日宣布与阿斯利康制药达成临床合作协定。根据美国证券交易委员会披露文件，双方将针对IDEAYA研发的IDE849与阿斯利康的Imfinzi（度伐利尤单抗）联合疗法，开展针对广泛期小细胞肺癌的临床评估。
根据协议安排，IDEAYA将作为临床试验的申办方，主导研究推进；阿斯利康则负责提供其抗PD-L1抗体Imfinzi。此次合作旨在探索IDE849在DLL3上调实体瘤治疗领域的潜力，目前IDEAYA正在积极推进该药物的全球一期临床试验。
值得注意的是，IDE849作为一款靶向DLL3蛋白的创新疗法，在临床前研究中已显示出对特定肿瘤类型的显著抑制活性。此次与阿斯利康的强强联合，有望加速该药物在难治性肿瘤领域的开发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.